MM-102 manufacturers
- MM-102
-
- $33.00
-
2026-07-16
- CAS:1417329-24-8
- Purity: 99.99%
- Supply Ability: 10g
- MM-102
-
-
2026-02-02
- CAS:1417329-24-8
- Min. Order: 5mg
- Purity: 99%HPLC
- Supply Ability: 2000tons
|
| Product Name: | MM-102 | | Synonyms: | MM-102;Cyclopentanecarboxamide, 1-[[(2S)-5-[(aminoiminomethyl)amino]-2-[[2-ethyl-2-[(2-methyl-1-oxopropyl)amino]-1-oxobutyl]amino]-1-oxopentyl]amino]-N-[bis(4-fluorophenyl)methyl]-;HMTase Inhibitor IX;1-[[(2S)-5-[(Aminoiminomethyl)amino]-2-[[2-ethyl-2-[(2-methyl-1-oxopropyl)amino]-1-oxobutyl]amino]-1-oxopentyl]amino]-N-[bis(4-fluorophenyl)methyl]cyclopentanecarboxamide];CS-2007;HMTASE INHIBITOR IX;MM102;MM 102;MM-102;MM-102 TFA Salt;MM-102 USP/EP/BP | | CAS: | 1417329-24-8 | | MF: | C35H49F2N7O4 | | MW: | 669.8 | | EINECS: | | | Product Categories: | Inhibitors | | Mol File: | 1417329-24-8.mol |  |
| | MM-102 Chemical Properties |
| density | 1.26±0.1 g/cm3(Predicted) | | storage temp. | Store at -20° C | | solubility | insoluble in H2O; ≥22.6 mg/mL in EtOH; ≥67 mg/mL in DMSO | | form | Powder | | pka | 12.90±0.20(Predicted) | | color | White to off-white | | InChIKey | RZKSQRIPRKWVBU-MHZLTWQESA-N | | SMILES | C1(NC(=O)[C@@H](NC(=O)C(CC)(NC(=O)C(C)C)CC)CCCNC(N)=N)(C(NC(C2=CC=C(F)C=C2)C2=CC=C(F)C=C2)=O)CCCC1 |
| | MM-102 Usage And Synthesis |
| Uses | MM-102 is a small molecule WDR5/MLL1 protein-protein interaction inhibitor. MM-102 in bone marrow cells transduced with MLL1-AF9 fusion construct decreases the expression of HoxA9 and Meis-1, two critical MLL1 target genes in MLL1 fusion protein mediated leukemogenesis. | | Biological Activity | mm-102 is an antagonist of mll1 with ic50 value of 2.4nm [1].mixed lineage leukemia 1 (mll1) is a histone h3 lysine 4 (h3k4) methyltransferase. the interaction of mll1 and wdr5 is essential for mll1 enzymatic activity and is a target for the treatment of acute leukemia. mm-102 is a peptidomimetic of mll1. it has a high binding affinity to wdr5 with ic50 value of 2.4nm [1].mm-102 is reported to reduce the expression of mll1 targeted genes hoxa9 and meis-1 in mll1-af9 transduced murine cells. since these two genes are required for mll1 mediated leukemogenesis, mm-102 is found to inhibit cell growth of leukemia cells harboring mll1 fusion proteins. it dose-dependently inhibits the cell growth in the mv4;11 and kopn8 cell lines with ic50 values both of 25μm[1]. | | in vivo | MM-102 (15 mg/kg; i.p.; once daily for 7 days) inhibits tumor progression in primary CCA model mice[3].
MM-102 (15 mg/kg; i.p.; once daily for 7 days) inhibits p16INK4a gene expression in IRI mice and reduces renal fibrosis and renal inflammation in IRI mice[4]. | Animal Model: | Ischemia-reperfusion injury in mice[4] | | Dosage: | 15 mg/kg | | Administration: | i.p.; Once daily for 7 days | | Result: | Inhibited a-SMA protein expression.
Inhibited p-NF-kB (p65), IL-1b, TNF-a, and IL-6 mRNA expression.
|
| | target | MLL1 | | references | [1] karatas h, townsend ec, cao f, chen y, bernard d, liu l, lei m, dou y, wang s. high-affinity, small-molecule peptidomimetic inhibitors of mll1/wdr5 protein-protein interaction. j am chem soc. 2013 jan 16;135(2):669-82. |
| | MM-102 Preparation Products And Raw materials |
|